
biomed devic servic
reinforc challeng ahead zimmer
hold pt
bottom line reiter hold rate post result came slightli
ahead expect overal result indic challeng zimmer must
overcom resolv on-going oper issu prevent share loss regain
market share necessari compon acceler top-lin growth unlock
sharehold valu encourag candor manag continu
discuss oper cultur challeng remain cautiou given potenti
risk current timelin allevi supply/manufactur issu
think guidanc appropri conserv xfx sale
growth commentari impact oper ineffici remedi effort
emphas time requir turnaound
sum current valuat ep estim surpris
long-term investor start opportunist build posit next six
month particularli given manag provid enough forward inform
start piec togeth mosaic howev messag regard timelin
suppli new product turnaround sale momentum increasingli make
feel like late event reiter hold given expect share remain
range-bound top-lin growth look challeng supply/
manufactur issu weigh margin next month
top line post revenu cg/street estim
suppli issu continu weigh compani result share loss
across board particularli us emea region nonetheless apac
highlight xfx growth xfx hip continu benefit
weight legaci zimmer product less affect suppli
issu emea america declin xfx respect inventori
constraint key legaci biomet product continu impact compani abil
fulfil exist demand recaptur former custom
manufactur manag note fda recent conclud anoth inspect
warsaw manufactur facil result addit observ
said continu execut remedi effort left manag increment
confid abl resolv qualiti issu begin
meantim compani continu work consult refin manufactur
process well dual-sourc manufactur key product continu
think manufactur issu resolv remain cautiou given uncertainti
surround time cadenc recaptur lost custom
guidanc call manag provid financi guidanc report
sale growth expect compar previou estim
growth back posit fx impact midpoint sale
growth expect declin grow bracket previou xfx
estim lastli pro-forma ep guid rang compar
previou estimate/consensu manag provid detail
gm guidanc emphas om guidanc assum neg
impact qualiti remedi suppli ineffici throughout
canaccord genuiti global capit market group canaccord genuiti group inc cf tsx
recommend opinion express research report accur reflect research analyst person independ object view
compani secur subject report discuss herein
import inform pleas see import disclosur begin page document
pipelin updat manag reiter expect pipelin product
play import part compani return sustain revenu earn
growth note zimmer highlight recent launch stemless shoulder sidu
cementless persona trabecular metal tibia allow zimmer offer full
cementless knee help fill product portfolio addit manag
note recent fda approv next-gen rosa robot system brain procedur
look forward highlight launch persona revis knee total-
knee rosa robot platform track limit releas view
pipelin posit howev expect take least
product materi impact top-lin growth
zimmer report sale estim
street revenu support strength asia pacif higher fx
tailwind expect off-set weak america emea
compani continu neg impact manufactur constraint
quarter ahead expect compani continu lose share key us
hip/kne market addit qualiti remedi effort
manufacturing/suppli issu continu impact margin due higher product cost
includ dual sourc inventori outsid vendor invest
end adjust gross margin came y/i pro
forma oper margin y/i zimmer report
adjust ep compar our/consensu estim
figur result vs estim consensu
hold unchang target price april
biomed devic servic
overal performanceactualcg estimatebeat/miss beat/miss consensusbeat/missnet good gross pro-forma oper net revenu productactualcg estimatebeat/miss beat/miss growthnet revenu geographyactualcg estimatebeat/miss beat/miss growthnet number us million zimmer biomet hold
updat guidanc chang estim
call manag provid full-year financi guidanc report sale
growth expect back posit fx impact
midpoint sale growth expect declin /grow
adjust oper margin expect rang
compani adjust tax rate expect rang
free cash flow guid rang lastli pro-forma
ep guid rang made follow chang
estim
adjust revenu estim
pro forma ep estim
adjust revenu estim
pro forma ep estim
adjust revenu estim
pro forma ep estim
adjust revenu estim
pro forma ep estim
adjust revenu estim
pro forma ep estim
adjust revenu estim
pro-forma ep estim
figur chang estim
broad large-cap med-tech group current trade mean price-to-earnings multipl
valu zimmer discount large-cap med-tech group given
uncertainti surround remedi suppli issu impact revenu
margin sum slightli increas price target base
price-to-earnings multipl appli pro-forma ep
hold unchang target price april
biomed devic servic
figur matrix discount rate impli share price target
zimmer biomet
zimmer world-wide leader design develop manufactur market
reconstruct spinal implant trauma relat orthoped surgic product
hold unchang target price april
biomed devic servic
comp pe multipl price metric use price-to-earnings valuat analysisbroad large-cap medic devic price-to-earnings multipl adjust pro-forma figur incom statement
compani report canaccord genuiti estim detail financi model includ balanc sheet incom statement cash flow project avail may obtain contact canaccord genuiti sale person author analyst whose contact
inform appear front page report
hold unchang target price april
biomed devic servic
zimmer biomet incom statementcanaccord genuiti kyle except per share good devic gener asset op incom chg chg amort stk incom minor incom ep ep one-tim ep chg share gener oper rate adjust growth growth ep ex compani document canaccord genuiti estim figur pro forma revenu build
hold unchang target price april
biomed devic servic
zimmer biomet revenu buildcanaccord genuiti kyle euro yen fx impact impact fx growth growth zimmer biomet hold
